Key result
Aspirin and clopidogrel monotherapies yield similar cardiovascular and bleeding outcomes beyond one month post-PCI.
Why the study?
No previous studies had directly compared aspirin monotherapy to P2Y12 inhibitor monotherapy following short DAPT in ACS patients, where HBR status and ACS subtype may influence antiplatelet strategies.
Does aspirin monotherapy compared to clopidogrel monotherapy beyond 1 month after PCI improve cardiovascular or bleeding outcomes in patients with ACS?
RCT (n=4,353)
randomly assigned
Does aspirin monotherapy compared to clopidogrel monotherapy beyond 1 month after PCI improve cardiovascular or bleeding outcomes in patients with ACS?
Aspirin monotherapy and clopidogrel monotherapy beyond 1 month after PCI in ACS patients are associated with similar cardiovascular and bleeding outcomes up to 1 year, regardless of bleeding risk or ACS subtype.
Answers are grounded in this paper and cite their sources.
Permits either aspirin or clopidogrel monotherapy beyond 1 month post-PCI in ACS; confirms similar CV and bleeding outcomes across HBR and subtypes.
Background/Introduction No previous studies have directly compared aspirin monotherapy to P2Y12 inhibitor monotherapy following short dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS). High bleeding risk (HBR) status and ACS subtypes (ST-segment elevation myocardial infarction [STEMI] or non-ST-segment elevation-acute coronary syndrome [NSTE-ACS]) might be key determinants of appropriate antiplatelet strategies. Purpose We investigated the effects of aspirin versus clopidogrel within 1 year after percutaneous coronary intervention (PCI) in ACS patients, based on HBR or non-HBR and STEMI or NSTE-ACS. Methods In the STOPDAPT-3 trial, patients with ACS regardless of HBR or non-ACS with HBR were randomly assigned to either 1-month DAPT with aspirin and prasugrel followed by aspirin monotherapy (aspirin group) or 1-month prasugrel monotherapy followed by clopidogrel monotherapy (clopidogrel group).(1, 2) The present study exclusively included patients with ACS in the STOPDAPT-3. We compared aspirin and clopidogrel monotherapy beyond 30 days and up to 1 year by the 30-day landmark analysis, in the pre-specified subgroups stratified by HBR or non-HBR and STEMI or NSTE-ACS. The co-primary cardiovascular endpoint was a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or ischemic stroke; the co-primary bleeding endpoint was major bleeding by Bleeding Academic Research Consortium type 3 or 5. Results Among the total population of 5833 patients in the 30-day landmark analysis of the STOPDAPT-3, 4353 (74.6%) patients with ACS were included. 1711 (39.3%) patients had HBR and 2457 (56.4%) were STEMI. The crude hazard ratios (HRs) of aspirin compared to clopidogrel were not statistically significant for the co-primary cardiovascular endpoint in both the HBR/non-HBR subgroups (HBR: 7.1 and 8.0 per 100 person-year, HR 0.89, 95% confidence interval (CI) 0.61–1.30; non-HBR: 2.1 and 2.0 per 100 person-year, HR 1.08, 95%CI 0.61–1.90; interaction-P=0.59) and in the STEMI/NSTE-ACS subgroups (STEMI: 4.8 and 4.7 per 100 person-year, HR 1.01, 95%CI 0.68–1.50; NSTE-ACS: 3.1 and 3.8 per 100 person-year, HR 0.81, 95%CI 0.48–1.37; interaction-P=0.51). Similarly, the HRs for the co-primary bleeding endpoint were not significant in both the HBR/non-HBR subgroups (HBR: 2.6 and 3.6 per 100 person-year, HR 0.73, 95%CI 0.40–1.33; non-HBR: 0.4 and 0.6 per 100 person-year, HR 0.71, 95%CI 0.23–2.24; interaction-P=0.97) and STEMI/NSTE-ACS subgroups (HR 0.96, 95%CI 0.46–2.01, and HR 0.53, 95% CI 0.24–1.17; interaction-P=0.28). Conclusions In patients with ACS, aspirin monotherapy after 1-month DAPT and clopidogrel monotherapy after 1-month prasugrel monotherapy were associated with similar cardiovascular and bleeding outcomes beyond 1 month and up to 1 year after PCI, regardless of bleeding risk (HBR or non-HBR) and ACS subtypes (STEMI or NSTE-ACS).
No takes yet. Share an insight, caveat, or question.
Obayashi et al. (2025) conducted an RCT in Acute coronary syndrome (n=4,353). Aspirin monotherapy vs. Clopidogrel monotherapy was evaluated on Composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or ischemic stroke in the high bleeding risk (HBR) subgroup (HR 0.89, 95% CI 0.61-1.30). Aspirin monotherapy after 1-month DAPT yielded similar cardiovascular outcomes to clopidogrel monotherapy in ACS patients with high bleeding risk and without.
Synapse has enriched 10 related papers. Consider them for comparative context: